Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan
LONDON, Feb. 25 /PRNewswire/ -- The patent expiry of blockbuster molecules has resulted in large pharmaceutical companies confronting intense competition from generics. CEOs have had to rethink strategies and devise alternative approaches to maintain the growth of their organisation and satisfy st...
AMA Alliance Warns Parents About Smoking in 'The Incredible Hulk,' Other Summer Blockbusters
AMA Alliance, Legacy Foundation, Leading Public Health Advocates Call for R Rating for Films with Tobacco Imagery
CHICAGO, June 11 /PRNewswire/ -- The American Medical Association (AMA)
Alliance warned parents today of yet another Hollywood film that exposes
underage audiences to...
MedThink Hires Joe Conwell as Executive Creative Director
A seasoned veteran in the advertising industry, Conwell has a wealth of experience managing creative team campaigns for pharmaceutical blockbusters
such as Lovenox and Diovan and has executed successful launches for Exforge, Yaz, Kodak Health Imaging and GE Healthcare.
Conwell's national co...
Consumer Reports 'Best Buy Drug' for Enlarged Prostate Could Save Consumers Nearly $3,000 a Year
... 20 most commonly prescribed drugs in 2008 with 11 million prescriptions written.
"Flomax is just the latest in a series of drugs promoted as blockbusters
that, in fact, create more sticker shock than anything else," says Santa. "The advertising appeal to middle aged men capitalizes on something all men...
Acetaminophen, Cholesterol Drugs May Help Fight Stroke
... studies are in the May issue of Lancet Neurology .
Prior studies have suggested that the use of cholesterol-lowering statins -- which include the blockbusters
Crestor, Lipitor and Zocor -- can cut the risk of stroke for certain patients.
in the new study, French researchers reviewed 24 studies involving m...
2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics
...hree prescriptions filled will be generic," continued Spiers. "These trends are going to become even more pronounced moving forward as there are many blockbusters
in major therapeutic areas like cholesterol reducers due to come off patent in the coming three years. The volume of available generics will increase,...
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
...peutics. "His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters
Taxol(R) and Paraplatin(R) (carboplatin)."
Dr. Rozencweig is an Adjunct Associate Professor of Medicine at New York University and has authore...
The Top 10 Health Stories of 2008, from the Harvard Health Letter
... This year, about two-thirds of the prescriptions written by doctors were for generic drugs. Generic drugs have taken off for many reasons. Brand-name blockbusters
(Fosamax, Zocor, and Zoloft) have lost their patent protection in recent years. The Medicare Part D prescription plans have loaded up their formularie...
Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation
...arty payers and consumers, claiming that McKesson engaged in a
scheme to fraudulently inflate the price of more than 400 prescription
drugs, including blockbusters
such as Prozac, Lipitor, Zocor, Vioxx and
On March 18, 2008, Judge Patti Saris for a second time rejected
McKesson's motions to dismiss the ca...
Making and Marketing of Pharmaceutical Megabrands
... CHAPEL HILL, N.C., June 20 /PRNewswire/ -- blockbusters
discovered, they are built! To build blockbusters, companies must start
early, listen carefully, and spend wisely. The recipe for success cont...
blockbusters in Medical Technology
blockbusters in Biological Technology
Though pharma growth slides, blockbusters reach new record
The global pharmaceutical market failed to reach double-digit growth in 2004 for the first time in about nine years. Key reasons for this focused on concerns over drug safety, pricing and competition from generic drugs as major products had their patents expire.
Let's take a look at how the ma...
Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young
...our paradigm-shifting trends that promise to accelerate the transition to sustainable business models:
Generics: Generics based on today's top blockbusters
should loosen governments' and insurers' budgetary constraints and mitigate pricing pressures on innovative drugs, permitting better margins.
Women's Surgery Recorded for the First Time on '4K' Digital Cinema is Presented at the AAGL Congress
...he session also included a projection of the largest high definition
(HD) 3d surgical images ever. Wearing glasses reminiscent of today's 3d
U23D and Journey to the Center of the Earth,
participating surgeons felt as if they could "reach out and join the
operation". These images were enable...
Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines
...key functionality areas pertaining
to Pharma Industry such as:
-- Resources and strategies required to gain crucial market access -- Creating blockbusters
in an increasingly competitive marketplace -- Publications strategies that give credibility and increase reputation -- Key to building effective b...
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
... the Max Planck Institute of Biochemistry, whose
pioneering gene technology-based and oncology-focused research led to the
development of the oncology blockbusters
Herceptin(R) and Sutent(TM)*. U3
Pharma was established in 2001 and currently employs 27 people, the
majority of whom work directly in research and de...
As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
... new industry entrants configured
specifically to succeed in the changed pharmaceutical landscape.
"Continuing yesterday's R&D focus on developing blockbusters
secure success in the future," according to Terri Cooper, Ph.D., a
principal in the Life Sciences practice of Deloitte Consulting LLP.
Big Pharma already has a generic strategy, but needs new direction
...hrough drug. A substantial portion of Big Pharma's revenue is dependent on blockbuster drugs. This means that Big Pharma is constantly looking for new blockbusters
to take the place of drugs that will be coming off patent or exclusivity protection and become subject to generic competition.
Blockbuster drugs ha...
Top 20 big pharmas represent majority of world pharma market
..., the leading therapeutic classes of drugs and the drug blockbusters, super blockbusters
and mega blockbusters.
Though the number of drug blockbusters
is on the rise as key Big Pharma companies increasingly globalize their pro...
Biotech flourishes in 2005 while Big Pharma is on the decline
In general, Big Pharma is still in trouble as a number of their blockbuster drugs come off in patent in the next few years and with few potential new blockbusters
in the works. M&A activity, except for J&J's go at medical device company Guidant (which almost failed when Boston Scientific took a run at Guidant it...
First half of 2006 roundup: Big Pharma trumps biotech
...tt Labs and Eli Lilly). In Pfizer's case, it is surely due to investor concern about Pfizer's product portfolio and the impact of generics and few new blockbusters
on the horizon. Pfizer has just announced that it has a war chest of $17 billion to acquire new products that will generate in excess of $1 billion ea...